Oral reactive capillary hemangiomas induced by SHR-1210 in the treatment of non-small cell lung cancer: a case report and literature review

Abstract

Background Antibodies to PD-1 and PD-L1 have remarkably improved the overall survival of many patients with advanced solid tumors. SHR-1210 is an anti-PD-1 monoclonal antibody. Dermatologic reactive capillary hemangiomas (RCH) were the most common and unique drug-related AEs of SHR-1210, but rare on oral mucosa and gastrointestinal mucosa. Herein we report a case of RCH occurred in oral mucosa during the clinical trials of SHR-1210 in the treatment of non-small cell lung cancer. Case presentation A male in his 60 s with a history of non-small cell lung cancer received injection of anti-PD-1 monoclonal antibodies SHR-1210. The patient developed drug-related RCH on skin after the first injection and began to have gingival hyperplasia one year after the first injection which gradually increased in size and affect eating and speaking. Anti-PD-1 treatments were continued. After periodontal treatment, two oral lesions and one skin lesion were surgically removed. Similar histological manifestation was found in all three lesions as reactive capillary hemangiomas. All lesions had a good prognosis without recurrence on oral mucosa within one year after surgery. Conclusions Oral reactive capillary hemangiomas could be induced by SHR-1210 in the treatment of non-small cell lung cancer. Surgical resection is an effective treatment with a good prognosis.

Hepatic cavernous hemangioma developed in non-small cell lung cancer patients after receiving Camrelizumab treatment: two case reports

“…Zhou et al. reported that oral mucosal hemangiomas can have a favorable prognosis when treated with local surgical excision within one year ( 33 ). Li et al.…”

Reactive cutaneous capillary endothelial proliferations of the eyelids induced by camrelizumab: A case report

“…According to a previous clinical trial, the RCCEPs were found as multiple, diffuse red papules or macules with clear boundaries, which gradually enlarged during treatment, accompanied by recurrent haemorrhage without pain or pruritus, and mostly regressed spontaneously with a median time of 211 days ( 24 ). Although RCCEPs are widely distributed over the skin and mucosa, the head and neck, trunk and extremities are the most commonly affected areas, with the mucosa, sclera, gingiva, nasal cavity, buccal mucosa, lip and tongue reported in a few cases ( 24 , 27 , 33 , 34 ). Although RCCEPs are usually small lesions with a maximum diameter of 2 mm, as reported by previous clinical trials ( 24 , 29 ), one case report showed that a RCCEP located on the inner thigh in a patient with esophageal squamous cell carcinoma treated with SHR-1210 was ~40 mm ( 24 ), and another case report showed that an oral RCCEP on the gingiva in a patient with non-small cell lung cancer treated with SHR-1210 was 15x7 mm ( 33 ).…”

“…Although RCCEPs are widely distributed over the skin and mucosa, the head and neck, trunk and extremities are the most commonly affected areas, with the mucosa, sclera, gingiva, nasal cavity, buccal mucosa, lip and tongue reported in a few cases ( 24 , 27 , 33 , 34 ). Although RCCEPs are usually small lesions with a maximum diameter of 2 mm, as reported by previous clinical trials ( 24 , 29 ), one case report showed that a RCCEP located on the inner thigh in a patient with esophageal squamous cell carcinoma treated with SHR-1210 was ~40 mm ( 24 ), and another case report showed that an oral RCCEP on the gingiva in a patient with non-small cell lung cancer treated with SHR-1210 was 15x7 mm ( 33 ). To the best of our knowledge, no cases of ocular RCCEPs have been reported in previous studies.…”

Immune checkpoint inhibitor induced colitis and arthritis: A case report

“…The emergence of immune checkpoint inhibitors marks a new era in cancer therapy, and their continuous evolution has brought major breakthroughs in cancer treatment. [ 1 ] As the preferred treatment for advanced cancer, immune checkpoint inhibitors have achieved remarkable success in melanoma, non-small cell lung cancer, esophageal squamous cell carcinoma and other tumors. [ 2 ] Programmed cell death protein-1 (PD-1) is a cell surface receptor present on T cells.…”